Literature DB >> 26216862

Therapeutic potential of cannabis-related drugs.

Stephen P H Alexander1.   

Abstract

In this review, I will consider the dual nature of Cannabis and cannabinoids. The duality arises from the potential and actuality of cannabinoids in the laboratory and clinic and the 'abuse' of Cannabis outside the clinic. The therapeutic areas currently best associated with exploitation of Cannabis-related medicines include pain, epilepsy, feeding disorders, multiple sclerosis and glaucoma. As with every other medicinal drug of course, the 'trick' will be to maximise the benefit and minimise the cost. After millennia of proximity and exploitation of the Cannabis plant, we are still playing catch up with an understanding of its potential influence for medicinal benefit.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabinoids; Drugs of abuse; Therapeutic potential

Mesh:

Substances:

Year:  2015        PMID: 26216862     DOI: 10.1016/j.pnpbp.2015.07.001

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  27 in total

1.  Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.

Authors:  Amey Dhopeshwarkar; Natalia Murataeva; Alex Makriyannis; Alex Straiker; Ken Mackie
Journal:  J Pharmacol Exp Ther       Date:  2016-12-07       Impact factor: 4.030

Review 2.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 3.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

4.  Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

Authors:  María Gómez-Cañas; Gemma Navarro; Paula Morales; Dow P Hurst; Francisco J Carrillo-Salinas; Laura Lagartera; Ruth Pazos; Pilar Goya; Patricia H Reggio; Carmen Guaza; Rafael Franco; Javier Fernández-Ruiz; Nadine Jagerovic
Journal:  J Med Chem       Date:  2016-07-06       Impact factor: 7.446

5.  FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.

Authors:  Huan Huang; Avery L McIntosh; Gregory G Martin; Danilo Landrock; Sarah Chung; Kerstin K Landrock; Lawrence J Dangott; Shengrong Li; Ann B Kier; Friedhelm Schroeder
Journal:  Biochemistry       Date:  2016-09-02       Impact factor: 3.162

6.  Cannabinoids from Cannabis sativa L.: A New Tool Based on HPLC-DAD-MS/MS for a Rational Use in Medicinal Chemistry.

Authors:  Michele Protti; Virginia Brighenti; Maria Rita Battaglia; Lisa Anceschi; Federica Pellati; Laura Mercolini
Journal:  ACS Med Chem Lett       Date:  2019-01-29       Impact factor: 4.345

7.  Use of Cannabinoids for Spasticity and Pain Management in MS.

Authors:  Hardeep Chohan; Ariele L Greenfield; Vijayshree Yadav; Jennifer Graves
Journal:  Curr Treat Options Neurol       Date:  2016-01       Impact factor: 3.598

8.  Marijuana's Influence on Pain Scores, Initial Weight Loss, and Other Bariatric Surgical Outcomes.

Authors:  Frank L Bauer; William T Donahoo; Harris W Hollis; Adam G Tsai; Brian J Pottorf; Jason M Johnson; Lori J Silveira; Farah A Husain
Journal:  Perm J       Date:  2018

Review 9.  Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions.

Authors:  Shyuan T Ngo; Jia D Mi; Robert D Henderson; Pamela A McCombe; Frederik J Steyn
Journal:  Degener Neurol Neuromuscul Dis       Date:  2017-07-25

Review 10.  Cannabinoids and the expanded endocannabinoid system in neurological disorders.

Authors:  Luigia Cristino; Tiziana Bisogno; Vincenzo Di Marzo
Journal:  Nat Rev Neurol       Date:  2019-12-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.